Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.45 USD
Change Today +0.335 / 3.02%
Volume 5.8M
ZIOP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

ziopharm oncology inc (ZIOP) Snapshot

Open
$11.21
Previous Close
$11.11
Day High
$11.93
Day Low
$11.15
52 Week High
03/20/15 - $14.40
52 Week Low
10/8/14 - $2.31
Market Cap
1.3B
Average Volume 10 Days
4.7M
EPS TTM
$-0.31
Shares Outstanding
114.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZIOPHARM ONCOLOGY INC (ZIOP)

ziopharm oncology inc (ZIOP) Related Bloomberg News

View More Bloomberg News

ziopharm oncology inc (ZIOP) Related Businessweek News

No Related Businessweek News Found

ziopharm oncology inc (ZIOP) Details

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing cancer therapies. The company is employing novel gene expression, and control and cells technologies to deliver cell-based therapies for the treatment of cancer. Its technology platform employs Intrexon Corporation’s RheoSwitch Therapeutic System technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is being evaluated in clinical studies of the immune system cytokine interleukin-12 for the treatment of breast and brain cancer. The company’s synthetic immuno-oncology programs, in collaboration with Intrexon Corporation, also include chimeric antigen receptor T cell (CAR-T) approaches and other cell based approaches that use non-viral gene transfer methods for scalability. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

27 Employees
Last Reported Date: 02/26/15

ziopharm oncology inc (ZIOP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $230.3K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $411.3K
Compensation as of Fiscal Year 2013.

ziopharm oncology inc (ZIOP) Key Developments

ZIOPHARM Oncology, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

ZIOPHARM Oncology, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $340,000 compared to $200,000 a year ago. Loss from operations was $10,596,000 compared to $6,719,000 a year ago. Net loss was $10,401,000 or $0.09 per basic and diluted share compared to $8,903,000 or $0.09 per basic and diluted share a year ago. For the year, the company reported revenue of $1,373,000 compared to $800,000 a year ago. Loss from operations was $43,499,000 compared to $57,713,000 a year ago. Net loss was $31,781,000 or $0.31 per basic and diluted share compared to $57,107,000 or $0.66 per basic and diluted share a year ago.

Intrexon Corporation and ZIOPHARM Oncology Announce Licensing Agreement with The University of Texas MD Anderson Cancer Center

Intrexon Corporation and ZIOPHARM Oncology announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. The licensed technologies arise from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota. The Cooper and Hackett laboratories have pioneered the design and clinical investigation of novel chimeric antigen receptor (CAR) T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications. When combined with Intrexon’s technology suite and ZIOPHARM’s clinically tested RheoSwitch Therapeutic System® interleukin-12 modules, the resulting proprietary methods and technologies may help realize the promise of genetically modified CAR T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy. Under the terms of the agreement, MD Anderson shall receive consideration of $100 million; $50 million from each Intrexon and ZIOPHARM, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies.

ZIOPHARM Oncology, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:30 PM

ZIOPHARM Oncology, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jonathan J. Lewis, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $11.45 USD +0.335

ZIOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $13.15 USD +0.58
Dynavax Technologies Corp $22.70 USD +0.33
Eurocine Vaccines AB kr2.85 SEK +0.05
Genocea Biosciences Inc $11.62 USD +0.04
Inovio Pharmaceuticals Inc $8.29 USD +0.195
View Industry Companies
 

Industry Analysis

ZIOP

Industry Average

Valuation ZIOP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 857.6x
Price/Book 35.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 924.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit www.ziopharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.